Phosphodiesterase 10A regulates alcohol and saccharin self-administration in rats

Neuropsychopharmacology

Volumn 39, Issue 7, 2014, Pages 1722-1731

  Logrip, Marian L ^a   Vendruscolo, Leandro F ^a   Schlosburg, Joel E ^a   Koob, George F ^a   Zorrilla, Eric P ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Alcohol use disorder; dorsal striatum; operant oral self administration; phosphodiesterase 10A enzyme; post traumatic stress disorder; reinforcement

Indexed keywords

ALCOHOL; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; SACCHARIN; UNCLASSIFIED DRUG; 2-(4-(PYRIDIN-4-YL-1-(2,2,2-TRIFLUOROETHYL)-1H-PYRAZOL-3-YL)PHENOXYMETHYL)QUINOLINE SUCCINIC ACID; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; ALCOHOL DERIVATIVE; BETA CYCLODEXTRIN DERIVATIVE; ENZYME INHIBITOR; PDE10A PROTEIN, RAT; PYRAZOLE DERIVATIVE; QUINOLINE DERIVATIVE; SWEETENING AGENT;

ADULT; ALCOHOL CONSUMPTION; ANIMAL EXPERIMENT; ARTICLE; AVERSION; CONDITIONED PLACE AVERSION; CONTROLLED STUDY; CORPUS STRIATUM; DORSOLATERAL STRIATUM; ENZYME INHIBITION; INSTRUMENTAL CONDITIONING; MALE; MOTOR ACTIVITY; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; SELF ADMINISTRATION TEST; STRESS; ANALYSIS OF VARIANCE; ANIMAL; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG EFFECTS; DRUG SELF ADMINISTRATION; METABOLISM; REINFORCEMENT; WISTAR RAT;

ALCOHOLS; ANALYSIS OF VARIANCE; ANIMALS; BETA-CYCLODEXTRINS; CONDITIONING, OPERANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; ENZYME INHIBITORS; MALE; MOTOR ACTIVITY; PHOSPHORIC DIESTER HYDROLASES; PYRAZOLES; QUINOLINES; RATS; RATS, WISTAR; REINFORCEMENT (PSYCHOLOGY); REINFORCEMENT SCHEDULE; SACCHARIN; SELF ADMINISTRATION; SWEETENING AGENTS;

EID: 84900527030     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.20     Document Type: Article

References (49)

1. Bakshi VP, Alsene KM, Roseboom PH, Connors EE (2012). Enduring sensorimotor gating abnormalities following predator expos ure or corticotropin-releasing factor in rats: A moDel for PTSD-like information-processing Deficits Neuropharmacology 62: 737-748.
2. Belin D, Jonkman S, Dickinson A, Robbins TW, Everitt BJ (2009). Parall el and interactive learning processes within the basal ganglia: Relevance for the unDerstanding of addiction. Behav Brain Res 199: 89-102.
3. Calabresi P, Gubellini P, Centonze D, Picconi B, Bernardi G, Che rgui K et al (2000). Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term Depression and long-term potentiation, opposing forms of synaptic plasticity. J Neurosci 20: 8443-8451.
4. Ca labresi P, Gubellini P, Centonze D, Sancesario G, Morello M, Giorgi M et al (1999). A critical role of the nitric oxiDe/cGMP pathway in corticostriatal long-term Depression. J Neurosci 19: 2489-2499.
5. Carelli RM (2002). The nucleus accumbens and reward: Neurophysiological investigations in behaving animals. Behav Cogn Neurosci Rev 1: 281-296.
6. Colombo G, Agabio R, Lobina C, Reali R, Zocchi A, Fadda F et al (1995). Sardinian alcohol-preferring rats: A genetic animal moDel of anxiety. Physiol Behav 57: 1181-1185.
7. Cottone P,Sabino V,Nag y TR,Coscina DV,Zorrilla EP,2007, Feeding microstructure in diet-induced obesity susceptible versus resistant rats: Central effects of urocortin 2, J Physiol 583(Part 2, 487-504.
8. Driessen M, Schulte S, LueDecke C, Schaefer I, Sutmann F, Ohlmeier M et al (2008). Trauma and PTSD in patients with alcohol, drug, or dual DepenDence: A multi-center study. Alcohol Clin Exp Res 32: 481-488.
9. Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi S, Okumura K et al (1999). Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem 274: 18438 -18445.
10. Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, Graf R et al (2009). Phosphodiesterase 10A inhibitor activity in preclinical moDels of the positive, cognitive, and negative symptoms of schizophr enia. J Pharmacol Exp Ther 331: 574-590.
11. Hu W, Lu T, Chen A, Huang Y, Hansen R, Chandler LJ et al (2011). Inhibition of phosphodiesterase-4 Decreases ethanol intake in mice. Psychopharmacology (Berl) 218: 331-339.
12. Jeanblanc J, He DY, Carnicella S, Kharazia V, Janak PH, Ron D (2009). Endogenous BDNF in the dorsolateral striatum gates alcohol drinking. J Neurosci 29: 13494-13502.
13. Jeanblanc J, Logrip ML, Janak PH, Ron D (2013). BDNF-mediated regulation of ethanol consumption requires the activation of the MAP kinase pathway and protein synthesis. Eur J Neurosci 37: 607-612.
14. Kheirbek MA, Britt JP, Beeler JA, Ishikawa Y, McGehee DS, Zhuang X (2009). ADenylyl cyclase type 5 contributes to corticostriatal plasticity and striatum-DepenDent learning. J Neurosci 29: 12115-1 2124.
15. Liddie S, AnDerson K, Paz A, Itzhak Y (2012). The effect of phosphodiesterase inhibitors on extinction of cocaine-induced conditioned place preference in mice. J Psychopharmacol 26: 1375-1382.
16. Logrip ML, Zorrilla EP (2012). Stress history increases alcohol intake in relapse: Relation to phosphodiesterase 10A. Addict Biol 17: 920-933.
17. Loughney K, SnyDer PB, Uher L, Rosman GJ, Ferg uson K, Florio VA (1999). Isolation and characterization of PDE10A, a novel human 30, 50-cyclic nucleotiDe phosphodiesterase. Gene 234: 109-117.
18. McCarthy E, Petrakis I (2010). EpiDemiology and management of alcohol DepenDence in individuals with post-traumatic stress disorDer. CNS Drugs 24: 997-1007.
19. Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005). Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10: 79-104.
20. Mumford GK, Holtzman SG (1990). Methylxanthines e levate reinforcement threshold for electrical brain stimulation: Role of aDenosine receptors and phosphodiesterase inhibition. Brain Res 528: 32-38.
21. Nawrocki AR, Rodriguez CG, Toolan DM, Price O, Henry M, Forrest G et al (2013). Genetic Deletion and pharmacological inhibition of PDE10A protects mice from diet-induced obesity and insulin resistance. Diabetes 63: 300-311.
22. Nestby P, VanDerschuren LJ, De Vries TJ, MulDer AH, WarDeh G, Hogenboom F et al (1999). Unrestricted free-choice ethanol selfadministration in rats causes long-term neuroadaptations in the nucleus accumbens and caudate putamen. Psychopharmacology (Berl) 14 1: 307-314.
23. Nishi A, Kuroiwa M, Miller DB, OCallaghan JP, Bateup HS, Shuto T et al (2008). Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J Neurosci 28: 10460-10471.
24. Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H et al (2012). Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148: 421-433.
25. Paxinos G, Watson C (1998). The Rat Brain in Stereotaxic Coordinates. 4th edn AcaDemic Press: New York, NY.
26. Perez-Torres S, Miro X, Palacios JM, Cortes R, Puigdomenech P, Mengod G (2000). Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and [3H]rolipram binding autoradiography. Comparison with monkey and rat brain. J Chem Neuroanat 20: 349-374.
27. Piccart E, Gantois I, Laeremans A, De Hoogt R, Meert T, Vanhoof G et al (2011). Impaired appetitively as well as aversively motivated behaviors and learning in PDE10A-Deficient mice suggest a role f or striatal signaling in evaluative salience attribution. Neurobiol Learn Mem 95: 260-269.
28. RoDefer JS,Saland SK,Eckrich SJ (2012, Selective phosphodiesterase inhibitors improve performance on the ED/ID cognitive task in rats, Neuropharmacology,62, 1182-1190.
29. Sabino V, Cottone P, Koob GF, Steardo L, Lee MJ, Rice KC et al (2006). Dissociation between opioid and CRF1 antagonist sensitive drinking in Sardinian alcohol-preferring rats. Psychopharmacology (Berl) 189: 175-186.
30. Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF et al (2008). Preclinical characterization of selective phosphodiesterase 10A inhibitors: A new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 325: 681-690.
31. Seeger TF, Bartlett B, Coskran TM, Culp JS, James LC, Krull DL et al (2003). Immunohistochemical localization of PDE10A in the rat brain. Brain Res 985: 113-126.
32. Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L et al (2006a ). Inhibition of the striatum-enriched phosphodiesterase PDE10A: A novel approach to the treatment of psychosis. Neuropharmacology 51: 386-396.
33. Siuciak JA, McCarthy SA, Chapin DS, Fujiwara RA, James LC, Williams RD et al (2006b ). Genetic Deletion of the striatumenriched phosphodiesterase PDE10A: EviDence for altered striatal function. Neuropharmacolog y 51: 374-385.
34. Smith SM, Uslaner JM, Cox CD, Huszar SL, Cannon CE, Vardigan JD et al (2012). The novel phosphodiesterase 10A inh ibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey. Neuropharmacology 64: 215-223.
35. SoDerling SH, Bayuga SJ, Beavo JA (1999). Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc Natl Acad Sci USA 96: 7071-7076.
36. Sotty F, Montezinho LP, Steiniger-Brach B, Nielsen J (2009). Phosphodiesterase 10A inhibition modulates th e sensitivity of the mesolimbic dopaminergic system to D-amphetamine: Involvement of the D1-regulated feedback control of midbrain dopamine neurons. J Neurochem 109: 766-775.
37. Stam R (2007). PTSD and stress sensitisation: A tale of brain and body Part 2: Animal moDels. Neurosci Biobehav Rev 31: 558-584.
38. Stewart LP, White PM (2008). Sensory filtering phenomenology in PTSD. Depress Anxiety 25: 38-45.
39. Stinson FS, Grant BF, Dawson DA, Ruan WJ, Huang B, Saha T (2005). Comorbidity between DSM-IV alcohol and specific drug use disorDers in the United States: Results from the National EpiDemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend 80: 105-116.
40. Stinus L, Cador M, Zorrilla EP, Koob GF (2005). Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned pl ace aversion in rats. Neuropsychopharmacology 30: 90-98.
41. Threlfell S, Sammut S, Menniti FS, Schmidt CJ, West AR (2009). Inhibition of phosphodiesterase 10A increases the responsiveness of striatal p rojection neurons to cortical stimulation. J Pharmacol Exp Ther 328: 785-795.
42. Tolkamp BJ, Kyriazakis II (1999). To split behaviour into bouts, log-transform the intervals. Anim Behav 57: 807-817.
43. ValDez GR, Roberts AJ, Chan K, Davis H, Brennan M, Zorrilla EP et al (2002). Increased ethanol self-administration and anxietylike behavior during acute ethanol withdrawal and protracted abstinence: Regul ation by corticotropin-releasing factor. Alcohol Clin Exp Res 26: 1494-1501.
44. ValDez GR, Zorrilla EP, Rivier J, Vale WW, Koob GF (2003). Locomotor suppressive and anxiolytic-like effects of urocortin 3, a highly selective type 2 corticotropin-releasing factor agonist. Brain Res 980: 206-212.
45. Vendruscolo LF, Barbier E, Schlosburg JE, Misra KK, Whitfield TW Jr., Logrip ML et al (2012). Cortic osteroid-DepenDent plasticity mediates compulsive alcohol drinking in rats. J Neurosci 32: 7563-7571.
46. Weber M, Breier M, Ko D, Thangaraj N, Marzan DE, Swerdlow NR (2009). Evaluating the antipsyc hotic profile of the preferential PDE10A inhibitor, papaverine. Psychopharmacology (Berl) 203: 723-735.
47. Wen RT, Zhang M, Qin WJ, Liu Q, Wa ng WP, Lawrence AJ et al (2012). The phosphodiesterase-4 (PDE4) inhibitor rolipram Decreases ethanol seeking and consumption in alcohol-preferring fawn-hooDed rats. Alcohol Clin Exp Res 36: 2157-2167.
48. West AR, Grace AA (2004). The nitric oxiDe-guanylyl cyclase signaling pathway modulates membrane activity States and electrophysiological properties of striatal medium spiny neurons recorDed in vivo. J Neurosci 24: 1924-1935.
49. Zhao Y, Weiss F, Zorrilla EP (2007). Remission and resurgence of anxiety-like behavior across protracted withdrawal stages in ethanol-DepenDent rats. Alcohol Clin Exp Res 31: 1505-1515.